Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389000 | 0.90 | GPR119 (0.77) | GPR119ALDH1A1MAPT | |
| SCHEMBL27652119 | 0.86 | GPR119 (0.81) | GPR119ALDH1A1MAPTRHOANEK2 | |
| SCHEMBL5262728 | 0.85 | GPR119 (0.61) | GPR119ALDH1A1MAPTPDE10A | |
| SCHEMBL1673701 | 0.78 | GPR119 (0.58) | GPR119ALDH1A1MAPT | |
| SCHEMBL27631842 | 0.76 | GPR119 (0.70) | GPR119ALDH1A1MAPTRHOANEK2 | |
| SCHEMBL388361 | 0.76 | GPR119 (1.00) | GPR119ALDH1A1MAPTGAA | |
| SCHEMBL1673803 | 0.74 | GPR119 (0.77) | GPR119MAPT | |
| SCHEMBL1673770 | 0.73 | GPR119 (0.43) | GPR119ALDH1A1 | |
| SCHEMBL5263490 | 0.73 | GPR119 (0.45) | GPR119ALDH1A1MAPTPDE10A | |
| SCHEMBL6250384 | 0.72 | GPR119 (0.44) | GPR119ALDH1A1MAPTRHOANEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | disclosed |